

1 **Bilirubin is not associated with urinary bladder cancer risk and prognosis: A Mendelian**
2 **Randomization Study in the UK Biobank**

3

4 Nadezda Lipunova* ^{1,2,3}, Richard T Bryan¹, Maurice Zeegers ^{1,2}

5 ¹Institute of Cancer and Genomic Sciences, University of Birmingham, United Kingdom

6 ²Department of Complex Genetics, Care and Public Health Research Institute, School for

7 Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands

8 ³Centre for Computational Biology, University of Birmingham, United Kingdom

9

10 Correspondence Address:

11 Nadezda Lipunova

12 Institute of Cancer and Genomic Sciences,

13 University of Birmingham,

14 United Kingdom, B15 2TT

15 Email: nxl689@student.bham.ac.uk

16 n.lipunova@maastrichtuniversity.nl

17 Tel. Nr.: +44029189097

18

19 Number of words in Abstract: 198

20 Number of words in the main text: 1,827

21 Running Title: Bilirubin and Bladder Cancer Risk

22 Keywords: bilirubin, bladder cancer, risk, prognosis, Mendelian Randomization

23

24

25

26

27

28

29

30

31

32

33 **ABSTRACT**

34 **Background**

35 Mutations in *UGT1A* gene have been associated with the development and prognosis of
36 urinary bladder cancer (UBC). *UGT1A* proteins are involved in a spectrum of detoxification
37 processes, hence the biological mechanism between *UGT1A* and UBC is difficult to
38 elucidate. Concurrently, mild hyperbilirubinemia, caused by alterations in *UGT1A*, has been
39 associated with multiple health outcomes. We have investigated the potential effect of mild
40 hyperbilirubinemia on UBC risk and prognosis, using a Mendelian Randomization (MR)
41 approach in the UK Biobank.

42 **Methods**

43 Data on 1,281 UBC patients and 4,071 controls was available for a two-stage least squares
44 MR estimation with rs6742078 as an instrumental variable. First, linear regression was fitted
45 to establish the relationship between the rs6742078 and bilirubin levels (total and
46 unconjugated). Secondly, bilirubin values were used to predict tested outcomes under a
47 logistic model. Both stages were adjusted for participant sex, smoking status, and age.

48 **Results**

49 MR analysis showed no significant effects of bilirubin levels on UBC risk (total bilirubin:
50 OR=1.02, 95% CI: 0.99-1.04; unconjugated bilirubin: OR=1.02, 95% CI: 0.99-1.05). No effects
51 were observed for events of UBC recurrence, progression, or survival.

52 **Conclusion**

53 Our study suggests mild hyperbilirubinemia is not associated with urinary bladder cancer
54 risk and prognosis.

55 INTRODUCTION

56 Urinary bladder cancer (UBC) poses a great burden for patients and healthcare systems, but
57 the clinical management has seen little change over the last few decades [1, 2]. Genetic
58 discoveries are a useful tool for investigating UBC development and enhance patient care.
59 However, elucidating the biological mechanisms behind the effect of genetics that would
60 help identify clinical targets offers a challenge.

61 Previous studies have identified the relevance of single nucleotide polymorphisms (SNPs) in
62 the *UGT1A* gene in UBC development, namely rs11892031 [3], rs17863783 [4], and
63 rs7571337 [5]. Moreover, reports for *UGT1A* effects being modified by smoking [6] is
64 especially relevant for the smoking population, as impaired metabolite clearance may result
65 in a longer exposure to tobacco-related carcinogens. Importantly, the evidence is lacking
66 whether *UGT1A* mutations are also relevant for UBC prognosis. One study assessing SNPs in
67 *UGT1A* (rs11892031 and rs17863783) for UBC prognosis did not find any significant results
68 [7].

69 Interestingly, a mutation in the *UGT1A*28* locus is a principal cause for Gilbert's syndrome
70 (GS). GS is a benign condition with global prevalence of about 5-10%, clinically present as
71 mildly elevated bilirubinaemia [8, 9]. Among affected, the expression of the bilirubin UDP-
72 glucuronosyltransferase (UGT) is reduced to about 30% of normal hepatic glucuronidating
73 activity [10, 11]. Rs6742078, located close to the *UGT1A*28* TATA box polymorphism was
74 found to explain roughly 18% of the total serum bilirubin and can be used as a proxy in
75 genetic analyses [12].

76 Mildly elevated bilirubinaemia has been associated with various health outcomes,
77 specifically protection against heart disease, diabetes, and overall mortality [9, 13]. It is
78 difficult to establish whether hyperbilirubinemia is the actual causal agent for these benefits
79 or merely a correlated marker, but the use of Mendelian Randomization (MR) makes it
80 possible to decipher its' role in human health. MR studies on bilirubinaemia and
81 cardiovascular disease [14], stroke [15], and non-fatty liver disease [16] showed bilirubin is
82 unlikely to play a role in these traits. On the other hand, a report on diabetes risk indicates
83 increased bilirubin levels exhibit a protective effect [17]. It has to be noted most MR studies
84 (with the exception of Luo *et al.* [16]) have only considered total serum bilirubin (TB) levels.
85 Instead, high TB levels may reflect impaired liver function, and hence only unconjugated
86 bilirubin (UB) is hypothesized to offer health benefits, if any [9].

87 Despite *UGT1A* being associated with bladder cancer, the potential effect of mild
88 hyperbilirubinemia on UBC risk and outcomes have not yet been assessed. In the current
89 MR study, we aimed to investigate the association between TB and UB serum levels and the
90 risk of developing UBC, as well as UBC prognosis (recurrence, progression, and survival) in
91 the UK Biobank cohort [18, 19].

92

93 **METHODS**

94 **Study population**

95 UK Biobank is one of the largest population-based cohorts in the UK. Genetic and clinical
96 data is collected for over 500,000 participants, aged 40-69 at the time of recruitment (2006-
97 2010). Detailed descriptions on UK Biobank design, data collection, and processing are
98 described in detail elsewhere [18, 19]. For the analysis on UBC prognosis, the sample was
99 limited to UBC patients only (International Classification of Diseases (ICD) codes of C67.0,
100 C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0 (ICD10) and 1880, 1882,
101 1884, 1886, 1888, 1889, 2337 (ICD9)).

102 For analyses on UBC risk, a random sample of 5000 participants were drawn as controls.

103 After data cleaning procedures, there were 1,281 UBC patients and 4,071 controls with
104 clinical and genetic data available for analysis.

105 **SNP selection**

106 Rs6742078 was chosen as the instrumental variable (IV) for bilirubin levels. Rs6742078
107 shows high correlation ($r^2 > 0.8$) with the causative locus for GS and has been successfully
108 used for other MR studies on various phenotypes [15, 16, 17].

109 **Outcomes and exposures**

110 The overall risk of developing UBC was treated as a binary outcome.

111 Death was modelled as an overall (death vs no death) or a UBC-specific event (death vs no
112 death, when primary cause of death was assigned C67- (ICD10) or 188-related (ICD9) codes).

113 Prognostic endpoints (recurrence, progression) were modelled using data from Hospital
114 Episode Statistics (HES) and Death Registry data.

115 For recurrence, three conditions to be representative of an event. First, a transurethral
116 resection of a bladder tumour (TURBT) (OPCS4 code M42) is regarded to be enough to
117 signify a UBC event. Secondly, a time period longer than 4 months between
118 chemotherapeutic treatments into urinary bladder (OPCS4 codes M494/M495) was

119 considered to be substantial to correspond to two independent events. Thirdly, a UBC
120 diagnosis if an examination of the urinary bladder (OPCS4 code M45) was led by a relevant
121 intervention within 6 months. Relevant interventions were chemotherapeutic treatments
122 into urinary bladder, cystectomy, radiotherapy, and chemotherapy (OPCS4 codes of
123 M494/M495; M34; X65; X72; X292, X298, X308, X352, respectively).

124 UBC progression was considered to have taken place if either a TURBT (OPCS4 code M42) or
125 examination of the urinary bladder (OPCS4 code M45) was followed by interventions of
126 cystectomy (OPCS4 code M34) and/or radiotherapy (OPCS4 code X65) within 6 months.

127 Two recurrence and/or progression events were considered independent of one another if
128 time in between the records was greater than 3 months.

129 Bilirubin levels (micromoles per litre, umol/L) have been measured in the UK Biobank by
130 photometric colour analysis on a Beckman Coulter AU5800.

131 **Ethics and consent**

132 All UK Biobank participants have provided informed consent. Current research has been
133 conducted using the UK Biobank Resource under Application Number 42772.

134 **Genotype data quality control (QC) and imputation**

135 Detailed QC procedures on imputation in the UK Biobank are described elsewhere [19]. Our
136 analyses were restricted White British participants to avoid population stratification bias
137 [19].

138 **Statistical analysis**

139 F statistic was calculated to establish the instrument strength for our analyses [20]. The rule
140 of thumb is to consider an instrument acceptable if the F statistic is >10 [20].

141 Firstly, have tested the association between TB and UB levels with the following outcomes:
142 UBC risk, death, recurrence, and progression. For all analyses, logistic regression was fitted
143 while adjusting for participant sex, smoking status (ever vs never), and age at the time of
144 diagnosis (or recruitment for controls).

145 Secondly, we have used a two-stage least squares (2SLS) MR estimation on all outcomes
146 with rs6742078 as an IV. In the first stage, linear regression was fitted to establish the
147 relationship between the IV and bilirubin levels (separately for TB and UB) assuming an
148 additive model of inheritance. The value of bilirubin from the first step was used to predict
149 UBC outcomes in the second stage under a logistic model. Both stages were adjusted for
150 participant sex, smoking status (ever vs never), and age.

151 The difference between baseline characteristics between cases and controls was tested
 152 using Chi-square for categorical variables and t-test for continuous outcomes. Statistical
 153 significance was assumed at two-tailed $p < 0.05$ throughout the analysis.

154

155 RESULTS

156 The rs6742078 proved to be a valid instrument for the analyses, as the F statistic has been
 157 calculated as 1,701 for TB and 1,751 for UB (both $p < 0.001$).

158 Baseline characteristics of the cases and controls are presented in **Table 1**. UBC cases were
 159 significantly older (mean age=61.3 years) than the controls (mean age=57.4 years), and
 160 were more often male (cases=81.2%, controls=49.8%) as well as having history of smoking
 161 (cases=68.4%, controls=45.7%). However, bilirubin levels and rs6742028 status were
 162 comparable between bladder cancer patients and controls (TB among cases=9.92 $\mu\text{mol/L}$,
 163 TB among controls=9.66 $\mu\text{mol/L}$, $p = 0.07$; Chi-square p value for independence of rs6742028
 164 genotype between cases and controls was 0.52).

165 **Table 1. Descriptive characteristic of bladder cancer patients and controls in the UK**
 166 **Biobank.**

Variables	Controls (N=4,071)	UBC Cases (N=1,281)	p value
Age (mean years, SD)	57.4 (8.06)	61.3 (8.98)	<0.001
Sex			<0.001
Males (N, %)	2029 (49.8)	1040 (81.2)	
Females (N, %)	2042 (50.2)	241 (18.8)	
Smoking status			<0.001
Never (N, %)	2209 (54.3)	405 (31.6)	
Ever (N, %)	1862 (45.7)	876 (68.4)	
rs6742028 status			0.52
GG (N, %)	1796 (44.1)	575 (44.9)	
TG (N, %)	1801 (44.3)	546 (42.6)	
TT (N, %)	474 (11.6)	160 (12.5)	
Total bilirubin ($\mu\text{mol/L}$)	9.66 (4.28)	9.92 (4.51)	0.07
Unconjugated bilirubin ($\mu\text{mol/L}$)	7.86 (3.59)	8.02 (3.79)	0.18
NMIBC	NA	1181 (92.2)	NA
Recurrence	NA	512 (40.0)	NA
Progression	NA	50 (3.90)	NA
Death	NA	176 (13.7)	NA

167

168 For the subgroup analyses within the UBC cases, there were 512 recurrence, 50 progression,
 169 and 176 death events. Non-muscle-invasive bladder cancer (NMIBC) comprised a total of
 170 1,181 out of 1,281 UBC cases.

171 A multivariable-adjusted model for testing the effect of TB on overall UBC risk resulted in an
172 odds ratio (OR) of 0.99 (95% confidence interval (CI): 0.98-1.01, $p=0.43$) (**Table 2**) The
173 estimate was equivalent for UB (OR=0.99, 95% CI:0.97-1.01, $p=0.36$). For the events of UBC
174 recurrence, progression, and death, both TB and UB have indicated neutral effects with all
175 ORs being close to 1 (**Table 2**).

176 In the MR analysis on UBC risk, causal OR estimates were identical for TB and UB levels (TB:
177 1.02, 95% CI: 0.99-1.04, $p=0.18$; UB: 1.02, 95% CI: 0.99-1.05, $p=0.18$) (**Table 2**).

178 In the additional analyses on clinically-relevant phenotypes of NMIBC recurrence,
179 progression, and muscle-invasive bladder cancer (MIBC) death, no association was observed
180 in either observational model or MR analysis (data not shown).

181

182 **DISCUSSION**

183 In the current study, we have investigated the causal role of TB and UB in the development
184 of bladder cancer, as well as UBC prognosis. Rs6742028 showed to be a valid instrument for
185 estimating causality, however no association was observed with any of the tested
186 outcomes.

187 Mutations in the *UGT1A* cluster, located in 2q37.1, have been associated with UBC in
188 previous genetic studies [3, 4, 21, 22]. SNPs in *UGT1A* have shown both harmful [21] and
189 protective effects for the risk of developing *de novo* UBC [4, 22], but there is uncertainty if
190 *UGT1A* influences the disease course, especially in NMIBC. Lacombe *et al* evaluated the
191 effect of *UGT1A1**28 SNP *rs8175347* in a group of 189 NMIBC cases [23] and concluded that
192 it significantly increased the risk of recurrence, with a gene-smoking interaction present
193 (higher recurrence risk for ever smokers). Nevertheless, the many strata in the study
194 resulted in small subgroup sample sizes [23]; therefore, the findings must be replicated in
195 other cohorts to establish validity.

196 The UGTs, coded by the region, are involved in various processes of detoxification. Until
197 now, the most common hypothesis suggests that variations in the activity of UGTs may
198 confer to an altered speed and efficiency of carcinogen clearance, and thus have a role in
199 cancer development[24]. In fact, a mapping study of the T allele of *rs17863783* has been
200 shown it results in an increased mRNA expression of the *UGT1A6* in human liver tissue
201 cells[4]. As such, it is hypothesized increased *UGT1A6* function helps to facilitate faster
202 removal of carcinogens from the bladder epithelium[4, 6, 24].

203 However, the UGTs may have more than one mode of action, due to a variety of function.
204 Given that mild hyperbilirubinemia has been implicated to play a role in many conditions, it
205 was useful to investigate whether the alterations in *UGT1A*28*, resulting high blood
206 concentrations of bilirubin may also have an effect on UBC development and prognosis.
207 However, our study suggests such effects are unlikely and tobacco-related carcinogen
208 detoxification remains the most likely hypothesis for explaining the effect of *UGT1A*
209 mutations on UBC.
210 We acknowledge our study carries important limitations. First, prognostic events have been
211 modelled using an algorithm that makes use of HES, but none of the events have been
212 confirmed on a case-by-case basis. Moreover, some events had low sample sizes (e.g.
213 progression), and likely underpowered to detect an existing association.

214

215 **CONCLUSIONS**

216 To summarise, we have investigated the potential role of mild hyperbilirubinemia in UBC
217 risk and prognosis. Using an MR methods for estimating causal relationships, our study
218 suggests *UGT1A* locus contributes to bladder cancer via mechanisms other than elevated
219 bilirubin.

220 **Table 2. Mendelian randomization analysis for bilirubin and urinary bladder cancer risk and prognosis in the UK Biobank.**

	TOTAL BILIRUBIN						UNCONJUGATED BILIRUBIN					
	Multivariable adjusted model*			Mendelian Randomization Analysis			Multivariable adjusted model*			Mendelian Randomization Analysis		
	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value
UBC Risk	0.99	0.98-1.01	0.43	1.02	0.99-1.04	0.18	0.99	0.97-1.01	0.36	1.02	0.99-1.05	0.18
UBC Recurrence	0.99	0.97-1.02	0.58	1.00	0.96-1.05	0.98	0.99	0.96-1.02	0.60	1.00	0.95-1.05	0.98
UBC Progression	1.01	0.95-1.07	0.66	0.96	0.84-1.08	0.57	1.02	0.95-1.08	0.57	0.99	0.81-1.10	0.57
UBC Death	0.98	0.94-1.02	0.29	0.99	0.92-1.05	0.70	0.97	0.92-1.02	0.22	0.99	0.91-1.06	0.70

UBC-urinary bladder cancer; OR-odds ratio; CI-confidence interval,

*Adjusted for participant sex, age, and smoking status (ever vs never).

221 **Additional information:**

222 **Ethics Approval and consent to participate:** All procedures performed in studies involving
223 human participants were in accordance with the ethical standards of the institutional
224 and/or national research committee and with the 1964 Helsinki declaration and its later
225 amendments. or comparable ethical standards. Informed Consent: Informed consent was
226 obtained from all individual participants included in the study.

227 **Data availability**

228 UK Biobank data are available through a procedure described at

229 <http://www.ukbiobank.ac.uk/using-the-resource/>.

230 **Conflict of Interest:** The authors declare they have no conflict of interest.

231 **Funding:** No funding to declare.

232 **Author Contribution Statement:** NL designed and carried out the study and wrote the main
233 manuscript; RBT, MZ, and NL have reviewed the manuscript.

234

235 Table legends:

236 Table 1. Descriptive characteristic of bladder cancer patents and controls in the UK Biobank

237 Table 2. Mendelian randomization analysis for bilirubin and urinary bladder cancer risk and

238 prognosis in the UK Biobank.

239 REFERENCES

- 240 1. Park JC, Hahn NM. Bladder cancer: a disease ripe for major advances. *Clinical*
241 *advances in hematology & oncology : H&O*. 2014;12(12):838-45.
- 242 2. Berdik C. Unlocking bladder cancer. *Nature*. 2017;551(7679):S34-s5.
- 243 3. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, *et al*. A
244 multi-stage genome-wide association study of bladder cancer identifies multiple
245 susceptibility loci. *Nature genetics*. 2010;42(11):978-84.
- 246 4. Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M, Chatterjee N, *et al*. Mapping
247 of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression
248 and protects from bladder cancer. *Hum Mol Genet*. 2012;21(8):1918-30.
- 249 5. Wang J, Wu X, Kamat A, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic
250 variants of UDP-glucuronosyltransferases, and bladder cancer risk. *British journal of cancer*.
251 2013;108(11):2372-80.
- 252 6. Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, *et al*.
253 Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder
254 cancer. *Cancer Res*. 2013;73(7):2211-20.
- 255 7. Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel SL, *et al*.
256 Prognostic relevance of urinary bladder cancer susceptibility loci. *PLoS one*.
257 2014;9(2):e89164.
- 258 8. Hirschfield GM, Alexander GJ. Gilbert's syndrome: an overview for clinical
259 biochemists. *Annals of clinical biochemistry*. 2006;43(Pt 5):340-3.
- 260 9. Wagner KH, Shiels RG, Lang CA, Seyed Khoei N, Bulmer AC. Diagnostic criteria and
261 contributors to Gilbert's syndrome. *Critical reviews in clinical laboratory sciences*.
262 2018;55(2):129-39.
- 263 10. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, *et al*. The genetic
264 basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's
265 syndrome. *The New England journal of medicine*. 1995;333(18):1171-5.
- 266 11. Sugatani J. Function, genetic polymorphism, and transcriptional regulation of human
267 UDP-glucuronosyltransferase (UGT) 1A1. *Drug metabolism and pharmacokinetics*.
268 2013;28(2):83-92.
- 269 12. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, *et al*. Genome-
270 wide association meta-analysis for total serum bilirubin levels. *Human Molecular Genetics*.
271 2009;18(14):2700-10.
- 272 13. Wagner KH, Wallner M, Molzer C, Gazzin S, Bulmer AC, Tiribelli C, *et al*. Looking to
273 the horizon: the role of bilirubin in the development and prevention of age-related chronic
274 diseases. *Clinical science (London, England : 1979)*. 2015;129(1):1-25.
- 275 14. McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A.
276 Association between bilirubin and cardiovascular disease risk factors: using Mendelian
277 randomization to assess causal inference. *BMC cardiovascular disorders*. 2012;12:16.
- 278 15. Lee SJ, Jee YH, Jung KJ, Hong S, Shin ES, Jee SH. Bilirubin and Stroke Risk Using a
279 Mendelian Randomization Design. *Stroke*. 2017;48(5):1154-60.
- 280 16. Luo L, An P, Jia X, Yue X, Zheng S, Liu S, *et al*. Genetically Regulated Bilirubin and Risk
281 of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. *Frontiers in*
282 *Genetics*. 2018;9:662.
- 283 17. Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL, *et al*.
284 Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization
285 study. *Diabetes*. 2015;64(4):1459-69.

- 286 18. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, *et al.* UK biobank: an
287 open access resource for identifying the causes of a wide range of complex diseases of
288 middle and old age. *PLoS medicine*. 2015;12(3):e1001779.
- 289 19. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, *et al.* The UK Biobank
290 resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-9.
- 291 20. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
292 guide, glossary, and checklist for clinicians. *BMJ (Clinical research ed)*. 2018;362:k601.
- 293 21. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, *et*
294 *al.* Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is
295 associated with urinary bladder cancer risk. *Arch Toxicol*. 2012;86(9):1369-78.
- 296 22. Zhang Y, Sun Y, Chen T, Hu H, Xie W, Qiao Z, *et al.* Genetic variations rs11892031 and
297 rs401681 are associated with bladder cancer risk in a Chinese population. *Int J Mol Sci*.
298 2014;15(11):19330-41.
- 299 23. Lacombe L, Fradet V, Levesque E, Pouliot F, Larue H, Bergeron A, *et al.* Phase II Drug-
300 Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive
301 Bladder Cancer: A Gene-Smoking Interaction. *Cancer prevention research (Philadelphia, Pa)*.
302 2016;9(2):189-95.
- 303 24. Sundararaghavan VL, Sindhvani P, Hinds TD, Jr. Glucuronidation and UGT isozymes
304 in bladder: new targets for the treatment of uroepithelial carcinomas? *Oncotarget*.
305 2017;8(2):3640-8.
306